Overview

  • Product name

    CFM 2, AMPA receptor antagonist
  • Description

    Selective, non-competitive AMPA receptor antagonist
  • Biological description

    Selective, non-competitive AMPA receptor antagonist. ERK1/2 pathway inhibitor. Reduces CREB phosphorylation and shows antiproliferative effects. Shows potent, long-acting anticonvulsant effects in vivo.
  • Purity

    > 98%
  • CAS Number

    178616-26-7
  • Chemical structure

    Chemical Structure

Properties

References

This product has been referenced in:

  • Park JS  et al. Role of spinal cord alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors in complete Freund's adjuvant-induced inflammatory pain. Mol Pain 4:67 (2008). Read more (PubMed: 19116032) »
  • Stepulak A  et al. AMPA antagonists inhibit the extracellular signal regulated kinase pathway and suppress lung cancer growth. Cancer Biol Ther 6:1908-15 (2007). Read more (PubMed: 18059166) »
  • Citraro R  et al. Effects of non-competitive AMPA receptor antagonists injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy. Neuropharmacology 51:1058-67 (2006). Read more (PubMed: 16901515) »
  • De Sarro G  et al. Anticonvulsant activity and plasma level of 2,3-benzodiazepin-4-ones (CFMs) in genetically epilepsy-prone rats. Pharmacol Biochem Behav 63:621-7 (1999). Read more (PubMed: 10462191) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab146413.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up